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Abstract
Over the last decade, DNA microarray technology has provided a great contribution to the life sciences. The MicroArray
Quality Control (MAQC) project demonstrated the way to analyze the expression microarray. Recently, microarray
technology has been utilized to analyze a comprehensive microRNA expression profiling. Currently, several platforms of
microRNA microarray chips are commercially available. Thus, we compared repeatability and comparability of five different
microRNA microarray platforms (Agilent, Ambion, Exiqon, Invitrogen and Toray) using 309 microRNAs probes, and the
Taqman microRNA system using 142 microRNA probes. This study demonstrated that microRNA microarray has high intra-
platform repeatability and comparability to quantitative RT-PCR of microRNA. Among the five platforms, Agilent and Toray
array showed relatively better performances than the others. However, the current lineup of commercially available
microRNA microarray systems fails to show good inter-platform concordance, probably because of lack of an adequate
normalization method and severe divergence in stringency of detection call criteria between different platforms. This study
provided the basic information about the performance and the problems specific to the current microRNA microarray
systems.
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Introduction
Since the first DNA microarray paper demonstrated that
microarray technology can monitor multiple gene expression
profile in 1995 [1], DNA microarray technology has been
developed steadily. After the Human Genome Project was
finished, the ability of DNA microarray expanded to genome-
wide analysis of not only gene expression profiling, but also,
genome variation, epigenetics, DNA-protein interaction, and so
on. In the research field, these genome-wide analyses using
microarray technology have been providing deeper biological
insights for a decade. In the clinical field, the US Food and Drug
Administration (FDA) approved MammaPrintH as the first in vitro
diagnostic multivariate index assay (IVDMIA) in February, 2007.
Thus, microarray-based transcriptome devices started to be
utilized to stratify patients for personalized medicine. For the
quality control and standardization of microarray chips, the US
FDA initiated the MicroArray Quality Control project (MAQC) in
2005. A series of reports regarding the first phase of the MAQC
project was published in 2006 [2–7]. The MAQC report showed
intra platform consistency across test sites as well as a high level of
inter-platform concordance in terms of genes identified as
differentially expressed.
MicroRNAs are a class of small non-coding RNAs [19–23
nucleotides (nt)] that have been found in animal and plant cells. As
of today, 718 human microRNAs are registered in the miRBase
database (Release 13, March, 2009) [8–11]. MicroRNA genes are
transcribed as non-coding transcripts, and processed through a
series of sequential steps involving the RNase III enzymes, Drosha
and Dicer. The processed microRNAs are finally incorporated
into the RNA-induced silencing complex (RISC) to mediate target
mRNA repression of translation and/or degradation. It is reported
that microRNAs are involved in physiological and pathological
functions, such as the regulation of developmental timing and
pattern formation [12], restriction of differentiation potential [13],
chromatin rearrangements [14], and carcinogenesis [15]. Many of
the mechanistic details still remain unknown.
Recently, microarray technology has been utilized to analyze a
comprehensive microRNA expression profiling. Currently, several
platforms of microRNA microarray chips are commercially
available. As mentioned above, the MAQC Project is currently
underway for quality control and standardization of mRNA
expression microarray. However, no comparative and quality
controlstudy of microRNA microarray platforms has been reported
yet. Therefore, we compared repeatability and comparability of
microRNA microarray using five different platforms (Agilent,
Ambion, Exiqon, Invitrogen and Toray). In addition, we compared
quantitivity of microarray data generated from five different
platforms with that of quantitative RT-PCR (Taqman) method,
which is the golden standard method of microRNA measurement.
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Experimental design
This project repeatedly assayed two RNA sample types on a
variety of microRNA expression platforms at one laboratory. Our
preliminary experiments showed that the amount of microRNA
obtained from the same amount of total RNA depends on the
tissue types of the samples (data not shown). This finding suggested
that repeatability or comparability of microRNA microarray
analysis might depend on the amount of microRNA contained in
total RNA. To assess the reproducibility of microRNA microarray
data using the different tissue types, we chose both tissue samples,
which contain relatively small and large amounts of microRNA.
Our preliminary data shows that mouse liver tissue contains
relatively small amounts of microRNAs. Therefore, we used two
types of total RNA, FirstChoiceH Human Liver Total RNA
(Ambion, lot no. 040000129) and FirstChoiceH Human Prostate
Total RNA (Ambion, lot no. 050500710), in this study. In fact, the
amount of microRNAs in Human Liver Total RNA was smaller
than that of Human Prostate Total RNA (Figure 1).
Five commercially available microRNA microarray platforms
were tested: Agilent Technologies (AGL); Ambion Inc. (AMB);
Exiqon (EXQ); Invitrogen (IVG) and Toray Industries Inc. (TRY)
(Table 1). Four of the microarray providers used one-color
protocols where one labeled RNA sample was hybridized to each
microarray. The Invitrogen array was tested using a two-color and
dye-swapping protocol so that, at first, two RNA samples were
divided and differently labeled in red-green and green-red
combinations, and each combination of the RNA sample set was
simultaneously hybridized to a microarray.
Agilent and Toray used its own method or software to generate
a quantitative signal value and a qualitative detection call for each
probe on the microarray, whereas Ambion, Exiqon, and
Invitrogen did not specify the scanner or software to quantify
the signals of probes in the manufacturer’s protocol booklet. To
generate a qualitative call for probes, we asked the technical
support centers of Ambion, Exiqon, and Invitrogen about the
method of detection call. We followed the methods recommended
by their technical support center.
Probe mapping
The MAQC project had a probe mapping problem in that each
gene was detected by a differently designed probe between the
different microarray platforms [6]. In contrast to the MAQC
project, this cross-platform study of microRNA microarray has
much less variability of probe mapping, because of the short length
(18–23 nucleotides) of microRNAs. Instead of this probe mapping
problem, we faced a different kind of annotation problem, due to
the database version. The frequent update of the miRBase
microRNA database [16] causes the situation that different
microRNA platforms were designed based on A different version
of miRBase database. Between the versions, names of some
microRNAs were changed, and the sequence of some microRNAs
bearing the same names were slightly changed in length.
Therefore, we compared the sequences in the annotation list
provided by the manufacturers. The 309 microRNAs which had
the complete identical sequences probed in all different platforms
were included in this study to simplify the inter-platform
comparison and to avoid a bias based on miRBase version.
Figure 1. MicroRNA expression level in human liver and prostate tissues. For the microarray platforms, log2 transformed values of
representative signal intensity for detection call-positive microRNAs were plotted. For the Taqman analysis, Ct values of microRNAs were plotted. Red
and blue lines indicate Y=X line and regressed linear line, respectively. In all scatter plots. blue lines were shifted upward, which indicated that the
general microRNA expression level in human prostate was higher than in human liver.
doi:10.1371/journal.pone.0005540.g001
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It will be important to know whether all data follows a specific
distribution, e.g. Gaussian or not. Thus, we checked the
distribution profile of data used in this study (Figure S1 and
Table S1). MicroRNA microarray data have various distribution
profiles between different platforms, although microarray data
tend to have positive skewness (a right-side longer tail). It has been
reported that the number of genes that are expressed at a similar
level is approximately exponentially distributed in typical biolog-
ical samples [17]. However, the skewness and kurtosis of
microRNA microarray data were far smaller than those of the
exponential distribution (skewness=4, and kurtosis=9) (Table
S1). We also checked whether non-zero log2 data were normally
distributed, or not. However, non-zero log2 data did not fit to
normal distribution (Figure S1B). On the other hand, the log-ratio
data between two samples were approximately normally distrib-
uted (Figure S1C).
Intra-platform data repeatability
We examined microarray data for consistency within each
platform by reviewing the repeatability at two levels: the
quantitative signal values and the qualitative microRNA list
agreement. To assess the data consistency of quantitative signal
values, rank-correlation analysis and coefficient of variation (CV)
analysis were performed. In this analysis, only data of microRNAs
with positive detection call were used. Representative scatter plots
of microarray platforms and the Taqman system are displayed in
Figure 2A (scatter plots for all possible combinations between three
replicates were shown in Figure S4). The Spearman’s correlation
coefficients (Rs), and the coefficient of variation (CV) between the
three replicates was calculated using the 309 common micro-
RNAs. Different platforms had various ranges of Rs values (liver:
0.82-0.96, prostate: 0.89-0.99, respectively). Thus, the 2-sample t-
test and Mann-Whitney did not detect any significant difference
between liver and prostate using whole data sets. However, the Rs
values for prostate samples were constantly better than those for
liver samples (Paired t-test: p=0.0013, and Wilcoxon’s signed-
rank test: p=0.0005). It is reasonable that Rs values of liver were
lower than those of prostate, because higher signals in microarray
data tend to have smaller data variability in general.
The distribution of CV for each platform was displayed in
Figure 2B. Two platforms (AMB and EXQ) have low stringent
criteria for detection call, in that all microRNAs with positive
signal values after subtraction of background are considered as
detected. It is also reasonable that these two platforms have higher
CV values (both t-test and Mann-Whitney test: p,0.0001),
because these platforms include microRNAs with near-zero values.
In addition, the CV values of microRNA microarray platforms
ranged in equivalent level to those of the Taqman assay.
Next, we assessed the variation in log-ratio measurement. For
each platform, we performed triplicate experiments using human
liver and prostate samples. Thus, we can generate 9 (=363) log-
ratios (prostate/liver) for each microRNA. Then, we calculated the
Spearman’s correlation coefficients (Rs) between 9 sets of log-ratios
for the detected microRNAs, and visualized these Rs values inside
of green squares in a blue-white heat map (Figure 3). The means
and 95% confidence intervals (95%CI) of Rs values were listed in
Table S2. The Rs values were high and consistent in two platforms
(AGL, and TRY), in which protocol hybridization were performed
with agitation. Another reason for the inconsistency of log-ratio
values in AMB and EXQ might be the low stringent criteria of
detection call, which included microRNAs with near-zero values.
To assess variation in the qualitative measures, the percentage
of 309 microRNAs with concordant detection calls between
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PLoS ONE | www.plosone.org 3 May 2009 | Volume 4 | Issue 5 | e5540Figure 2. Intra-platform repeatability of quantitative assessment of microRNA expression. MicroRNA measurement of the same sample
(L: human liver, P: human prostate) was replicated three times. Only data of microRNAs with positive detection call were used for analysis. 2A: Scatter
plots show the correlation between replicate 1 and 2 (scatter plots for all possible combinations between three replicates were shown in Figure S4).
Spearman’s correlation coefficients (Rs) for replicates 1 vs. 2, 1 vs. 3, and 2 vs. 3 were calculated and summarized in lower table. Rs for the prostate
sample were generally better than those for the liver sample (p=0.0005, paired T-test). This finding suggests that repeatability of microRNA would
depend on the sample cell type, and that repeatability in the case of samples expressing A higher amount of microRNAs would be better. TAQ
(Taqman analysis) obtained the best Rs values despite a slightly wider spread of data. It might be a result from wider range of microRNA detection
(microarray: 2
16, Taqman: about 2
20). 2B: Box plot of coefficient of variation (CV) for microRNA detection platforms. The coefficient of variation for
each microRNA assessment was calculated by a formula, CV=(standard deviation/mean)6100, and the distribution of CV was plotted in the box plot
diagram. Bold line: median, bottom and top line of the box: first and third quantile, respectively.
doi:10.1371/journal.pone.0005540.g002
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PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5540replicates of the same sample type was calculated on each platform
(line graphs in Figure 4A). As expected, microarray signals from
liver samples were generally weaker than those of prostate samples
(Figure 1). Thus, the percent of detected microRNA subset in liver
samples was significantly smaller than that in prostate samples
(Figure 4A, paired T-test: p=0.0003, and Wilcoxon’s signed rank
test: p=0.0005). In the current study, we used criteria of detection
call of microRNAs that the manufacturers recommended.
However, the stringency of these detection call criteria was very
different. For AMB and EXQ array, all microRNAs with positive
signal were handled as detected microRNAs, whereas other
manufacturers provided their own formula as detection call
criteria. This difference in the detection call stringency may result
in the divergence of detected microRNA percentage. Thus,
detected microRNA percentage of AMB and EXQ array were
less stable in three replicates (t-test and Mann-Whitney test of
standard deviation, p=0.0011 and 0.004, respectively) than the
others.
Intra-platform concordance in detected microRNA list was
shown inside of green squares in Figure 4B and 4C. It is
reasonable that AMB and EXQ with instable percentage of
detected microRNAs also had higher inconsistency in the detected
microRNA list than the others. Intra-platform concordance in a
list of differentially expressed microRNAs was illustrated inside of
green squares in Figure 5. The means and 95%CIs of agreement
percentages were listed in Table S3. AGL and TRY had more
than 90% concordance of differentially expressed microRNAs list
within intra-platform replicates.
Inter-platform data comparability
MicroRNA expression values generated on different platforms
cannot be directly compared because unique labeling methods and
probe sequences will result in variable signal distributions for
probes that hybridize to the same target microRNAs. (Figure S1)
Alternatively, the relative expression between a pair of sample
types should be maintained across platforms. For this reason, we
examined the microarray data for comparability between
platforms by reviewing liver sample to prostate sample expression
values with two different levels: rank correlation of the log-ratio as
qualitative assessment, and the microRNA list agreement
(detection call and identification of differentially expressed
microRNAs) as qualitative assessment.
To show the inter-platform concordance in the detected
microRNA list, the percentage of 309 microRNAs with concor-
dant detection calls between replicates on different platforms was
calculated and visualized outside of green squares in Figure 4B and
4C. The median percentages of inter-platform detection concor-
dance were 74.0% and 72.1% for liver and prostate sample,
respectively. There was no statistical difference in detection call
concordance between liver and prostate samples. For both
samples, these percentages were widely distributed, ranging
56.3–97.9% and 58.2–95.9%, respectively, because the difference
in detection call stringency lead to a divergence in detection call
rate across the platforms.
The comparability of results across the platforms was also
examined using a rank correlation metric. For rank correlation,
only detected microRNAs from the common 309 gene list were
included in the analysis. Log-ratios for the differential expression
observed between liver sample replicates and prostate sample
replicates were calculated for the generally detected common
microRNAs and then compared across the platforms. The rank
correlations of the log-ratios are displayed visually in Figure 5A.
Good agreement was not observed between the platforms,
compared to the original MAQC report. In fact, the best
correlation was obtained between AGL and TRY (Rs=0.8717),
and the median rank correlation was 0.55 between the microarray
platforms.
For the list overlap of differentially expressed microRNAs, all
309 common genes were considered. A list of differentially
expressed microRNAs was generated for each platform and
compared to lists from the other platform. A percent score was
calculated to indicate the number of microRNAs in common
between each pair of platforms. The percentage of overlap for
each comparison is displayed in Figure 5. Note the graphic
comparisons are asymmetrical indicating the analysis is performed
in two directions. That is, the percentage of platform Y
microRNAs on the list from platform X can be different from
the percentage of platform X microRNAs on the platform Y list.
In contrast with one color platforms, IVG (two-color method)
identified A much lower number of differentially expressed
microRNAs, probably due to log-ratio compression (Figure 6).
Therefore, percentages of list overlap between IVG and one-color
platforms were generally low. AGL, EXQ and TRY had a good
concordance in terms of identifying differentially expressed
microRNAs.
Correlation to Taqman assay
In the MAQC project, the quantitative accuracy of several non-
microarray devices was checked, then quantitative RT-PCR
(Taqman system) was selected as a validation method of
microarray data. In the microRNA research field, several different
types of quantitative RT-PCR (qRT-PCR) methods are in use,
such as qRT-PCR using stem-loop shaped RT-primer, Taqman
system, Applied Biosystems) [18], qRT-PCR using locked nucleic
acid primers (Exiqon) [19], and qRT-PCR with poly-A tailing
(QIAGEN, Stratagene). In this study, we also used the Taqman
Figure 3. Rank correlation of log-ratios between intra- and
inter-platform replications. For each platform, microRNA expression
profiles in the liver and the prostate were measured three times by
independent microarray chips. Therefore, 9 (=363) combinations of
log-ratios (liver/prostate) for each microRNA was calculated. Then, 81
(=9 69) Spearman’s correlation coefficients (Rs) values were calculated,
and visualized in blue-white heat map. White indicates high correlation,
whereas blue means low correlation. Heatmaps by Pearson’s and
Kendall’s correlation coefficients were available in Figure S4.
doi:10.1371/journal.pone.0005540.g003
MicroRNA Microarray
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method most widely used. Further comparisons between each
microarray platform relative to the TaqMan assays are presented
as scatter plots in Figure 6. One hundred forty two microRNAs
were randomly selected from 309 common microRNAs to the
microRNA platforms, then the expression levels of these 142
microRNA in the human liver and prostate were measured by
Taqman system. Good correlation coefficients (Rs=0.85,0.86)
Figure 4. Repeatability and agreement of detection call. As a qualitative assessment of microRNA, A list of detected microRNAs should agree
between different platforms. Detection call of microRNA for each platform was performed according to different criteria recommended by the
manufacturer. 4A: The number of detected microRNAs. Closed circles: detected microRNAs, open circles: not detected microRNAs, white bar:
perfectly detected microRNAs, which were detected in all three replications, gray bar: perfectly not-detected microRNAs, which were not detected in
all three replications. For the Taqman analysis, amplified microRNAs within 40 cycles were considered as detected. 4B & C: Agreement rate of
detection call list between intra- (inside of green squares) and inter-platform (outside of green squares) replications using liver (4B) and prostate (4C)
samples. The percent agreement of detected microRNAs was calculated as the number of microRNAs detected by platform Y relative to the number
of microRNAs detected by platform X. Therefore, two blocks in A diagonally symmetric position are not always the same color, because the
denominators are different.
doi:10.1371/journal.pone.0005540.g004
MicroRNA Microarray
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platforms, especially IVG (two-color method), log-ratio compres-
sion (slope,1) was observed. In the original MAQC paper, a two
color method showed log-ratio compression in the comparison
with Taqman assays. Thus, our finding is a consistent result.
Figure 7 demonstrated microRNA list agreement of detected
microRNAs (Figure 7A and 7B) and differentially expressed
microRNAs (Figure 7C). For detection call of microRNAs, there
were few false positive and many false negative results. Thus, the
microarray method is a device with high specificity and less
sensitivity, compared to the Taqman assay. In identifying
differentially expressed microRNAs, high concordance ratios
(81.69%, 88.73%) to the Taqman assay were obtained in EXQ
and TRY platforms, respectively. In contrast, IVG has very low
true positive results, probably because two color method had a
severe log-ratio compression.
Discussion
The results of the current study provide information about the
potential advantages and problems of microRNA microarray
technologies as a tool providing microRNA expression data for
research and future clinical purposes.
In the original MAQC paper, the median values of CV for gene
expression microarray ranged from 5 to 20%, whereas those of
CV in this study ranged from 20 to 90%, approximately. We
wondered why the CV values in this study were much higher than
those in the MAQC paper, although the Rs values in this study
were similar to those in the MAQC papers. One possible
explanation was that the data distributions of the replicated data
sets were not well centered due to a lack of data normalization. For
the gene expression microarray analysis, data are generally
normalized under an assumption that the total amount of mRNA
is constant between different samples. However, microRNA
microarray data generated from the same amount of total RNA
were not normalized in general, because we know that the amount
of microRNA varies depending upon cell types, such as normal
tissue vs. cancer [15]. To assess whether this explanation is true or
not, we normalized the microRNA microarray data within
replicates of the same samples in the same platforms (Figure S2).
The CV values were drastically improved after the quantile
normalization within the same replicates. The median values of
CV in Figure S3 were significantly lower than those in Figure 3
(paired t-test, p=0.03813). This finding suggests that normalizing
microRNA microarray data would be beneficial to improve data
repeatability and consistency in situations when the amounts of
microRNAs in the samples are assumed to be constant.
Furthermore, we should develop a universal method that can
perform a reasonable normalization between different cell types
containing different amounts of microRNAs.
This normalization problem is associated not only with
microRNA microarrays, but also with the Taqman assay. Because
we have not discovered reliable housekeeping microRNAs, the
Taqman assay measures just Ct values without normalization,
which are obtained using the same amount of total RNA. This fact
may result in the relatively high CV values that are ranging in the
equivalent level to microRNA microarray platforms. In other
words, a similar level of repeatability would be a relative
advantage of microarray platforms to the Taqman system.
Another problem with microRNA microarray platforms is a
divergence in the stringency of the detection call criteria. The
detection call criteria should be adjusted to each platform, in order
to obtain reliable and repeatable data. However, too much
divergence in the percentages of detected microRNAs would result
in the disagreement in the results of further analyses, which may
induce underestimated impressions and reputations of microRNA
microarray technology. Therefore, this report emphasizes the
necessity of a larger project that will solve specific microRNA
problems, such as normalization and detection call stringency, and
that builds a consensus in all aspects of the microRNA microarray
analysis.
In the MAQC project, seven different platforms (Applied
Biosystems, Affymetrix, Agilent, Eppendolf, GE Healthcare,
Illumina, and NCI array) were compared [6]. In the current
study, five platforms (Agilent, Ambion, Exiqon, Toray, and
Invitrogen) were studied. Thus, only one company (Agilent) was
overlapped. This fact indicates that the tips developed in gene
expression microarray field are not inherited well into microRNA
microarray. One example is the hybridization method. Currently,
many gene expression microarray platforms employ a dynamic
hybridization method to generate repeatable and reproducible
data. In the current study, microRNA microarray platforms with
dynamic hybridization systems (AGL and TRY) showed relatively
better results than those with static hybridization systems. It is
easily imaginable that the addition of agitation into the
hybridization procedures of AMB, EXQ, and IVG platforms
would improve data quality. In the microRNA research field,
Luminex Corp. (Austin, TX) provides a beads-hybridization-based
microRNA detection system (FlexmiR). The beads-hybridization is
one form of the dynamic hybridization methods, and has high
Figure 5. Agreement in the list of differentially expressed
microRNAs. This graph indicates the concordance of microRNAs
identified as differentially expressed for pairs of platforms, labeled as X
and Y. A list of differentially expressed microRNAs between human liver
vs. human prostate was generated for each platform (using the 309
common microRNAs with $two-fold change) and compared for
commonality to other platforms. No filtering related to the qualitative
detection call was performed. The color of the square in the matrix
reflects the percent overlap of microRNAs on the list for the platform X
(listed in column) that are also present on the list for the platform Y
(listed in row). A light-colored square indicates a high percent overlap
between the microRNA lists at both platforms. A dark-colored square
indicates a low percent overlap, suggesting that most microRNAs
identified in platform X were not identified in platform Y. Note: the
graph is asymmetric and not complementary, for the same reason as in
Figure 4B and C.
doi:10.1371/journal.pone.0005540.g005
MicroRNA Microarray
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microRNAs only in the miRBase version 8 list, when we
performed the experiments. Therefore, we excluded this system
from the current study.
The updated version of the miRBase list will include newly
registered microRNAs. These newly added microRNAs are
expected to be expressed at relatively low levels. Therefore,
adding new microRNAs with low expression would cause poorer
performance in repeatability or reproducibility, even when using
the same platforms. It suggests that a standard set of microRNAs
would be needed to compare the performances between micro-
RNA microarray platforms designed according to different
miRBase versions.
In this study, we assessed the repeatability and comparability of
microRNA microarray among several commercially available
platforms. Different from mRNA expression microarray, micro-
RNA microarray requires another important characteristic in the
assay. For mRNA microarray, the probe(s) for each gene can be
Figure 7. Agreement of microRNA list between microarray platforms and the Taqman assay. MicroRNAs that were listed, or not listed in
both microarray and the Taqman assay, were considered as true positive (TP) or true negative (TN), respectively. MicroRNAs that were listed in either
microarray or Taqman assays, were handled as false positive (FP) or false negative (FN), respectively. 7A and B: These graphs indicated the
concordance of detection call between microarray platforms and the Taqman assay, using 142 microRNAs assayed by both microarray and the
Taqman system. 7C: This bar graph demonstrated the concordance of microRNAs identified as differentially expressed between microarray platforms
and the Taqman assay system.
doi:10.1371/journal.pone.0005540.g007
Figure 6. Correlation between microarray and Taqman data. The scatter plots compare the log-ratio differential expression values from each
microarray platform relative to values obtained by the Taqman assays. Each point represents a microRNA that was measured on both the microarray
and Taqman assays. Only microRNAs that were generally detected in both human liver and prostate were used in the comparisons. Among 142 total
microRNAs assayed by the Taqman system, the number of microRNAs analyzed for correlation to the Taqman assays are listed in the table. The red
and blue lines shown are the ideal Y=X line, and the regressed line from the scatter plots, respectively. Spearman’s correlation coefficients (Rs), slope
and Y intercept of regressed line were shown in the table.
doi:10.1371/journal.pone.0005540.g006
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cross-hybridization. However, the short length of microRNAs (18–
23 nucleotides) restricts the flexibility of probe design. Moreover,
there are many same-family microRNAs which have high
sequence homology. Thus, microRNA microarray requires an
ability to distinguish these same-family microRNAs with high
specificity. In this study, we did not assess the sequence specificity
of the microRNA microarray. This issue should be addressed in
future studies.
Currently, the MAQC project is on-going in the second phase,
and the US FDA released the second version of draft guidelines for
IVDMIA in July, 2007 (http://www.fda.gov/cdrh/oivd/guidance/
1610.pdf). Actually, several microarray platforms for mRNA
expression have already been approved and utilized in the clinical
field as IVDMIAs, e.c., MammaPrintH for breast cancer, and
PathworkH Tissue of Origin Test for unknown origin tumor.
Regarding the microRNA microarray, this study demonstrated that
some platforms of microRNA microarray have intra-platform
repeatability as high as that of the mRNA expression microarray
demonstrated in the MAQC papers. Thus, our finding indicated
that the microRNAmicroarraymayhave high potential asa clinical
diagnostic tool when good diagnostic microRNA markers are
available. To date, at the research level, many papers have
described the physiological and pathological significance of
microRNAs, and reported potential biomarker microRNAs.
However, the reproducibility of the microRNA microarray has
not been assessed by a multi-center study, such as the MAQC
project. Furthermore, there are some microRNA-specific problems
to be solved, such as building consensus on normalization of the
microRNA expression data and the specificity of microRNA
detection to distinguish microRNAs with high sequence homology.
Thus, a large-scale multi-center quality control project specific to
the microRNA microarray is required before its clinical application.
In a review article, Shendure, described that the next-
generation high throughput sequencer would replace DNA
microarray technology in the transcriptome research field [20].
The next-generation sequencing technology has been applied to
microRNA detection [21]. Is this the beginning of the end of the
microRNA microarray? As far as we know, the current report is
the first paper to compare the several platforms of microRNA
microarrays regarding their performances. We have not fully
evaluated the advantages and disadvantages of microRNA
microarray yet. Therefore, it is too early to answer this question
and it should be addressed in a near future study.
In conclusion, this study demonstrated that the microRNA
microarray has high intra-platform repeatability and comparabil-
ity to quantitative RT-PCR of microRNA. However, the current
lineup of commercially available microRNA microarray systems
fails to show good inter-platform concordance, probably because
of severe divergence in stringency of detection call criteria between
different platforms. This study provided the basic information
about the performance and the problems specific to the current
microRNA microarray systems.
Materials and Methods
MicroRNA microarray platforms
Five commercially available microRNA microarray platforms;
Agilent Technologies (Santa Clara, CA), Ambion (Austin, TX),
Exiqon (Vedbaek, Denmark), Invitrogen (Carlsbad, CA), and
Toray (Tokyo, Japan) were tested in this study. In all assays, we
performed microRNA microarray assays according to the
manufacturer’s protocols available in April, 2008.
RNA samples
Our preliminary experiments showed that the amount of
microRNA obtained from the same amount of total RNA depends
on the tissue types of the samples (data not shown). This finding
suggested that reproducibility or detection call rate of microRNA
microarray analysis might vary depending on the amount of
microRNA contained in the total RNA. To assess the reproduc-
ibility of microRNA microarray data using the different tissue
types, we chose both tissue samples, which contain relatively small
and large amount of microRNA. Our preliminary data shows that
mouse liver tissue contains A relatively small amount of
microRNAs. Therefore, we used two types of total RNA,
FirstChoiceH Human Liver Total RNA (Ambion, lot
no. 040000129) and FirstChoiceH Human Prostate Total RNA
(Ambion, lot no. 050500710), in this study. As shown in Figure 1,
microRNA expression level in human liver was lower than in
human prostate. For Ambion’s microRNA microarray, small
RNA fractions purified from these total RNAs were used. For
other microarrays, total RNAs were directly processed. The
amounts of total RNA used for the assays were decided according
to the manufacturer’s protocols (Table 1). The platform-specific
external controls were added to the samples prior to labeling for all
platforms.
Labeling and hybridization
For the Invitrogen microarray, RNA samples were labeled using
a two-color and dye-swapping protocol. For other microarrays, a
one-color protocol was used. Three replicate assays for each
sample were independently processed. In the two-color protocol,
two RNA samples differently labeled by Alexa 532 and Alexa 645
were simultaneously hybridized on the same microarray chip. In
addition, to normalize the dye-specific bias, RNA samples were
labeled by switched dye combination. The microarray data from
these two sets of two color scanning image were integrated. On the
other hand, in a one-color protocol, each RNA sample was labeled
using a single dye, and two RNA samples were hybridized
separately on two microarray chips. All target labeling and
hybridizations were performed in triplicate, according to the
manufacturer’s protocols. (Notes: A recent Exiqon protocol
utilizing agitated hybridization was not provided in April 2008,
when our experiments were performed)
Microarray chip scanning
(1) Agilent microarray. Microarray slides were scanned
using an Agilent microarray scanner G2505B (Agilent technology)
and microarray images were automatically analyzed using Feature
extraction
TM software, version 9.5.1.1 (Agilent technology). In this
study, the gTotalGeneSignal values were used as the feature
intensities, according to the procedures recommended by Agilent.
(2) Ambion microarray. Microarray slides were scanned
USING a ProScanArray
TM microarray scanner (PerkinElmer Inc.
Waltham, MA). For each scanning, a photomultiplier setting of the
red channel was manually adjusted to 55, and the obtained
microarray images were analyzed using the Genepix Pro
TM 4.0
software (Molecular Device, Sunnyvale, CA). Spots that might be
associated with artifacts were eliminated using software- and
visual-guided flags. In this study, the median values of the
foreground signal minus the local background were represented as
feature intensities.
(3) Exiqon microarray. Microarray slides were scanned
using Agilent microarray scanner G2505B and the obtained
microarray images were analyzed using the Genepix Pro
TM 4.0
software. Artifact-associated spots were eliminated both by
software- and visual-guided flags. In this study, the median
MicroRNA Microarray
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represented as feature intensities.
(4) Invitrogen microarray. Microarray slides were scanned
using Agilent microarray scanner G2505B and the microarray
image was analyzed using the Genepix Pro
TM 4.0 software. Spots
that might be associated with artifacts were eliminated using by
software- and visual-guided flags. In this study, the median values
of the foreground signal minus the local background were
represented as feature intensities.
(5) Toray microarray. Microarray slides were scanned using
ProScanArray
TM microarray scanner where the photomultiplier
settings of the red channel were manually adjusted according to
the procedures recommended by the manufacturer. Each
microarray was scanned three times, then merged into one data,
and the merged data were analyzed using the Genepix Pro
TM 4.0
software. Spots that might be associated with artifacts were
eliminated using software- and visual-guided flags. In this study,
the median values of the foreground signal minus the local
background were represented as feature intensities.
Microarray data processing
In ordinary mRNA expression microarray, it is a standard data
processing procedure to normalize the microarray data with an
assumption that the whole mRNA expression signal is constant
among the samples. However, in the microRNA analysis, the
amount of microRNA contained in the same amount of total RNA
varied depending on the tissue or cell types. All microarray data
were registered into NCBI’s Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/projects/geo/). The ac-
cession numbers ARE listed in Table S4 of Supporting information.
The detection call criteria
Detection call criteria for Agilent, Toray, and Invitrogen were
described in the manufacturers’ protocol handbook, whereas those
for Ambion and Exiqon were not available. Thus, we asked
customer support offices of Ambion and Exiqon about their
recommended detection call criteria (contacted in May–June,
2008). For the Agilent array, gIsGeneDetected values in output
data sheet were used for detection call. For Ambion and Exiqon
arrays, customer service offices of both manufacturers recom-
mended handling all spots with over 0 intensities as detected spots.
For the Invitrogen array, the lower limit of detection is eight times
the median local background of all array features. For the Toray
array, positive detection call was defined as spots in which signal
intensities showed greater than the upper limits of 95% confidence
interval of all blank spots’ signal intensities.
Real-time quantitative PCR for microRNA expression
To validate the microRNA expression in each sample, we
measured the expression of 171 microRNAs by using a qRT-PCR
platform: TaqMan microRNA Assays (Applied Biosystems Inc.)
and ABI 7300 Sequence Detector
TM. This qRT-PCR method
detects specifically mature microRNAs, but not precursor micro-
RNAs. To perform this TaqMan assay, we used the same amount
of total RNA, and Ct-values were recorded. Then, the value of
2
(40-Ct) represents the expression level of the target microRNA.
Probe mapping
The probe annotations for all microarray platforms and qRT-
PCR were provided by the manufacturer. The official annotation of
microRNAs in the miRBase Database (http://microrna.sanger.ac.
uk/) is being updated frequently. The release version of the official
database was 11.0whenthis studystarted.However,themicroRNA
annotation version used for the microarray probe design was
different among the five different microarray platforms in April
2008. Agilent and Toray are based on the Sanger miRBase
Database, release 10.1 and 11.0, respectively. Exiqon and
Invitrogen are based on the release 10.0, and Ambion is based on
the release 9.2. To analyze the different formats of microarray data,
we extracted microRNA expression data exactly matched to release
10.1. To compare the microRNA profile between two different
microarray platforms, we used all overlapped microRNAs available
in both microarray platforms. The number of human microRNAs
common among all five microarrays was 310. To validate
microRNA microarray data, randomly selected 146 human
microRNAs were measured by the Taqman qRT-PCR system.
Signal repeatability and reproducibility
To assess signal repeatability and reproducibility of each
microarray platform, we utilized the methods that the MAQC
Project used [6], such as calculating the Spearman’s correlation
coefficient (Rs), and the coefficient of variation (CV) of the signal
or Cy3/Cy5 values for one or two color method, respectively. The
CV for each microRNA assessment was calculated by a formula,
CV=(standard deviation/mean)6100.
MicroRNA list agreement
A list of detected microRNAs in each sample and the
differentially expressed microRNAs between two samples were
identified for each assay. The criteria of differential expression
were that a difference of two microRNA is greater than two-fold.
The percent agreement of microRNAs was calculated as the
number of microRNAs detected by platform Y relative to the
number of microRNAs detected by platform X. For the percent
agreement of differentially expressed microRNAs, the 95%
confidence interval of percent agreement between platforms was
estimated from distribution of percentages calculated from 81
(=9 69) possible combination of data sets (Figure 5 and Table S3).
Log ratio comparability
To compare the similarity of the log ratio for each microRNA
between each microarray platform, we determined the slope and
intercept of the orthogonal regression between pairs of the log
ratio in each microarray platform. The log ratio of each
microRNA was calculated as the average of log signals in the
liver sample minus the average of log signals in the prostate
sample. The slope and intercept are determined by the formula
y=ax+b, where ‘‘y’’ is the log ratio from platform Y, ‘‘x’’ is the log
ratio from platform X, and the ideal slope is 1. For the slope, the
difference from the ideal slope (a=1) indicates the compression or
expansion of the log ratios in one platform relative to the other.
For the intercept, the distance of zero means the platform-specific
bias between two microarray platforms.
Comparability between a pair of each platform was also
examined using Spearman’s rank correlations of the log ratios.
This value compares the relative position of a microRNA in the
platform X rank order of the log ratio (fold change) values against
its position in the platform Y rank order.
Concordance with qRT-PCR
The percentage of overlapping microRNAs between each
microarray platform and qRT-PCR was a measure of the
reproducibility of lists of differentially expressed microRNAs. We
considered that the agreement of detected microRNAs in each
sample and differentially expressed microRNAs between two
samples for each microarray platform. For each platform,
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measured three times by independent microarray chips. There-
fore, 9 (=363) combinations of log-ratios (liver/prostate) for each
microRNA was calculated. The microRNAs that had consistently
greater than or equal to two-fold difference in these 9 ratios were
assigned as differentially expressed microRNAs for each platform.
Because we considered that qRT-PCR was true, true positive (TP)
was detected in both of microarray and qRT-PCR, true negative
(TN) was not-detected in both of microarray and qRT-PCR, false
positive (FP) was only detected in microarray, and false negative
(FN) was only detected in qRT-PCR. The formula for accuracy is
(TP+TN)/(TP+TN+FP+FN).
Supporting Information
Figure S1 Distribution profile of microRNA microarray data
Histograms of microRNA microarray data. All 309 microRNA
data of each microarray platform were plotted in a histogram. In
addition, 142 microRNA data of Taqman RT-PCR data were
displayed in the same format. Negative log2 values were handled
as 0 (0=log21).
Found at: doi:10.1371/journal.pone.0005540.s001 (4.66 MB TIF)
Figure S2 Probability plots of microRNA microarray data
distribution. To show the normality of the distribution of non-zero
data, The probability plot of each data set was generated using non-
zero log2 values, excluding 2.5% of values in both sides. If
distribution of the data is normal, this probability plot would be a
line. In most of cases, kurtosis of the data distribution was around 2.
Found at: doi:10.1371/journal.pone.0005540.s002 (8.06 MB TIF)
Figure S3 Probability plots of the distribution of log-ratio values.
To demonstrate the normality of the distribution of log-ratio
values, probability plots of log-ratio data were generated using
95% of middle log-ratio data. Lilliefor’s test showed that the null
hypothesis was not rejected in EXQ and TRY, which means that
the distribution of log-ratio data in EXQ and TRY array were
quite similar to normal distribution. p: p-values of Lilliefor’s test.
Found at: doi:10.1371/journal.pone.0005540.s003 (3.62 MB TIF)
Figure S4 Scatter plots showing correlations between the same
replicates. Red and blue lines indicate the ideal Y=X line, and
linear regressed line of scattered dots. S1A,D: For one-color
platforms, representative signal values of microRNA were plotted.
S1E: For two-color platform (Invitrogen), log2-ratios (liver/
prostate) of microRNA were plotted.
Found at: doi:10.1371/journal.pone.0005540.s004 (9.50 MB TIF)
Figure S5 Effect of normalization on the rank-correlation of
microRNA microarray. At first, we performed quantile normal-
ization within the same replicates using one-color platform data.
Then, the Spearman’s correlation coefficients (Rs) were calculated.
Because the quantile normalization changes values of microRNAs
but not rank of microRNAs, Rs values in Figure 2 and Figure S3
were the same.
Found at: doi:10.1371/journal.pone.0005540.s005 (8.12 MB TIF)
Figure S6 Effect of normalization on the coefficient of variation
In contrast to Spearman’s correlation coefficients in Figure S3, the
coefficients of variation (CV) were drastically improved after the
quantile normalization within the same replicates. The median
values of CV in Figure S3 were significantly lower than those in
Figure 3 (paired t-test, p=0.03813). The CV of AGL and TRY
were within the range of CV demonstrated in the original MAQC
project paper.
Found at: doi:10.1371/journal.pone.0005540.s006 (5.07 MB TIF)
Figure S7 Correlation of log-ratios between intra- and inter-
platform replications. Heatmaps of Pearson’s correlation coeffi-
cients and Kendall’s rank correlation coefficients. Both heatmaps
had a similar pattern to heatmaps using Spearman’s correlation
coefficients in Figure 3.
Found at: doi:10.1371/journal.pone.0005540.s007 (6.08 MB TIF)
Table S1 Skewness and Kurtosis of microRNA microarray data
distribution Skewness and kurtosis of each data set was calculated
using all expression data or non-zero log2 data of 309 microRNAs.
A symmetric distribution has 0 skewness. A distribution with
positive skew has a longer right tail, while a distribution with
negative skew has a longer left tail. The kurtosis of the normal
distribution is 3. A high kurtosis distribution has a sharper peak
and longer, fatter tails, while a low kurtosis distribution has a more
rounded peak and shorter thinner tails. This table demonstrated
that microRNA microarray data tend to have a positive skewness.
Found at: doi:10.1371/journal.pone.0005540.s008 (0.03 MB
DOC)
Table S2 Rank correlation coefficients of log-ratios between
intra- and inter-platforms of microRNA microarray. For rank
correlation calculation, we used data of detected microRNAs that
meet the detection criteria of each manufacturer. Both prostate
and liver samples have triplicated data sets. Thus, 9 (=363) sets of
log-ratios (prostate/liver) of microRNAs were generated. For
intra-platform correlation, rank correlation coefficients of 36
(=9 6842) combinations were calculated, whereas, 81 (=969)
coefficients were calculated for inter-platform correlation. Upper
values: Spearman’s correlation coefficients, Lower values: 95%
confidence intervals.
Found at: doi:10.1371/journal.pone.0005540.s009 (0.03 MB
DOC)
Table S3 List agreement of differentially expressed microRNA
This table showed percentage of concordance in detecting
differentially expressed microRNAs. The values in the upper
portion of cells reflects the mean percent overlap of microRNAs
on the list for the platform X (listed in column) that are also
present of the list for the platform Y (listed in row), whereas the
values in the lower portion were 95% confidence intervals of the
mean percentage. A higher value indicates a high percent overlap
between the microRNA lists at both platforms. A lower value
indicates a low percent overlap, suggesting that most microRNAs
identified in platform X were not identified in platform Y.
Therefore, the table is asymmetric and not complementary.
Found at: doi:10.1371/journal.pone.0005540.s010 (0.03 MB
DOC)
Table S4 Accession numbers of microarray data All microarray
data were registered into NCBI’s Gene Expression Omunibus
(GEO) database (http://www.ncbi.nlm.nih.gov/projects/geo/).
All data were available to public on March 30, 2009.
Found at: doi:10.1371/journal.pone.0005540.s011 (0.04 MB
DOC)
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